Minerva Neurosciences
develops and commercializes clinical-stage products for the treatment of central nervous system diseases... Read moreMinerva Neurosciences
develops and commercializes clinical-stage products for the treatment of central nervous system diseases... Read more
News
Jun 01, 2026
FinanzNachrichten
Minerva Neurosciences: Minerva Neurosciences, Inc: Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
May 18, 2026
FinanzNachrichten
Minerva Neurosciences: Minerva Neurosciences, Inc: Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
May 05, 2026
FinanzNachrichten
Minerva Neurosciences: Minerva Neurosciences, Inc: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
Apr 02, 2026
Citybizlist
Minerva Neurosciences: Minerva Appoints Jim O'Connor as Chief Business Officer and General Counsel
Apr 02, 2026
Benzinga
Minerva Neurosciences: Minerva Announces Leadership Transition
Mar 31, 2026
Seeking Alpha
Minerva Neurosciences: Minerva Neurosciences: Plodding Ahead After Another Roluperidone Delay In Negative Symptoms Of Schizophrenia
Mar 25, 2026
Benzinga
Minerva Neurosciences: Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
Mar 12, 2026
Benzinga
Minerva Neurosciences: Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
Mar 11, 2026
Owler
Minerva Neurosciences, Inc.: Minerva Neurosciences's employee count changed from 8 in Dec 2024 to 7 in Dec 2025
Mar 11, 2026
FinanzNachrichten
Minerva Neurosciences: Minerva Neurosciences, Inc: Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
Minerva Neurosciences Competitors
1
2
3
4
5
6
7
8
9
10